Active Ingredient History
Cebranopadol is an opioid analgesic of the benzenoid class which is currently under development internationally by Grünenthal, a German pharmaceutical company, and its partner Depomed, a pharmaceutical company in the United States, for the treatment of a variety of different acute and chronic pain states. As of November 2014, it is in phase III clinical trials. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Chronic Pain (Phase 3)
Diabetes Mellitus (Phase 2)
Diabetic Neuropathies (Phase 2)
Heart (Phase 1)
Low Back Pain (Phase 2)
Neoplasms (Phase 3)
Osteoarthritis, Knee (Phase 2)
Pain (Phase 3)
Pain, Postoperative (Phase 2)
Pharmacokinetics (Phase 1)
Substance-Related Disorders (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue